Heron Therapeutics | HRTX - Ebitda

Stock Price
1.31
Daily Change
0.08 6.10%
Monthly
65.32%
Yearly
-42.26%
Q2 Forecast
1.24

Heron Therapeutics reported $-3.88M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
ALKERMES USD 80.26M 20.05M Mar/2026
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Eisai JPY 30.1B 6.62B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -314.19M 31.48M Dec/2025
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
Merck USD 6.3B 2.09B Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 40.24M 1.53M Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Surmodics USD 3.43M 1.9M Jun/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Veracyte USD 42.8M 488K Mar/2026
Vertex Pharmaceuticals USD 1.39B 48.8M Dec/2025